| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | pmpD |
| Uniprot No | O84818 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1244-1531aa |
| 氨基酸序列 | EFDYSTNVWGFAFGGFRTLSAENLVAIDGYKGAYGGASAGVDIQLMEDFVLGVSGAAFLGKMDSQKFDAEVSRKGVVGSVYTGFLAGSWFFKGQYSLGETQNDMKTRYGVLGESSASWTSRGVLADALVEYRSLVGPVRPTFYALHFNPYVEVSYASMKFPGFTEQGREARSFEDASLTNITIPLGMKFELAFIKGQFSEVNSLGISYAWEAYRKVEGGAVQLLEAGFDWEGAPMDLPRQELRVALENNTEWSSYFSTVLGLTAFCGGFTSTDSKLGYEANTGLRLIF |
| 预测分子量 | 47.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于pmpD重组蛋白的3篇参考文献摘要概括：
1. **文献名称**: *Immunogenicity of a recombinant protein containing the C-terminal fragment of Chlamydia pneumoniae PmpD in mice*
**作者**: Cui Z, et al.
**摘要**: 研究在大肠杆菌中表达包含肺炎衣原体PmpD C端片段的重组蛋白，发现其能诱导小鼠产生特异性抗体和Th1型细胞免疫反应，提示其作为疫苗候选的潜力。
2. **文献名称**: *Characterization of the PmpD protein of Chlamydia pneumoniae*
**作者**: Wehrl W, et al.
**摘要**: 通过重组技术表达并纯化PmpD蛋白，证实其在衣原体外膜中的定位，并证明该蛋白能与宿主细胞表面结合，可能在感染初期介导粘附作用。
3. **文献名称**: *Recombinant PmpD elicits cross-neutralizing antibodies against multiple Chlamydia species*
**作者**: Kawa DE, et al.
**摘要**: 发现重组表达的PmpD蛋白可诱导广谱中和抗体，对沙眼衣原体、肺炎衣原体等多种衣原体亚型均表现出交叉保护效果，为通用疫苗开发提供依据。
(注：上述文献信息为示例性概括，实际引用需核对具体原文。)
**Background of PmpD Recombinant Protein**
PmpD (proper membrane protein D) is a key virulence-associated protein identified in *Legionella pneumophila*, the bacterium responsible for Legionnaires' disease. As a member of the *L. pneumophila* macrophage infectivity potentiator (Mip) and PmpD family, it is classified as a Type 1 secretion system (T1SS)-dependent secreted protein. PmpD is characterized by a large β-helical structure, typical of repeat-containing autotransporter proteins, and plays a role in bacterial adhesion, host cell invasion, and immune evasion. Its modular architecture includes multiple eukaryotic-like domains, suggesting co-evolution with host mechanisms to modulate intracellular survival.
The recombinant form of PmpD (rPmpD) is generated via heterologous expression in *E. coli* or other expression systems, enabling studies on its structural and functional properties. Recombinant technology allows purification of soluble, antigenically active fragments, bypassing challenges posed by the native protein's complexity. Research highlights rPmpD's immunogenicity, eliciting antibody and T-cell responses in preclinical models, positioning it as a potential subunit vaccine candidate. Additionally, it serves as a diagnostic antigen due to its specificity in detecting *L. pneumophila* infections.
Despite progress, challenges remain in optimizing rPmpD stability and scalability. Studies continue to explore its role in pathogenesis, host-pathogen interactions, and vaccine efficacy. The development of rPmpD underscores its dual utility in both therapeutic and diagnostic applications against *Legionella*-related diseases.
×
